Clinical phenotype of COVID ‐19 vaccine‐associated myocarditis in Victoria, 2021–22: a cross‐sectional study
Medical Journal of Australia · 2025
DOI: 10.5694/mja2.52557 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Journal of Australia, 2025. Verfasst von Julia Smith und 12 weiteren Autor:innen. Beteiligte Einrichtung: Royal Children's Hospital Melbourne, Melbourne, VIC. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, Myocarditis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Objectives
To describe myocarditis as an adverse event after coronavirus disease 2019 (COVID‐19) vaccination, including a detailed description of clinical phenotypes and diagnostic test results and differences by age, sex, and degree of troponin level elevation. Study design Retrospective cross‐sectional study. Setting, participants Cases of suspected myocarditis following the administration of a COVID‐19 vaccine in Victoria during 22 February 2021 – 30 September 2022 reported to Surveillance of Adverse Events Following Vaccination In the Community (SAEFVIC), with symptom onset within 14 days of vaccination, and deemed to be confirmed myocarditis according to the Brighton Collaboration Criteria. Main outcome measures Demographic (sex, broad age group), vaccine, and clinical presentation characteristics; cardiac investigation results (troponin levels, electrocardiography, echocardiography, cardiac magnetic resonance imaging [cMRI]).
Results
Of 454 SAEFVIC reports of suspected COVID‐19 vaccine‐associated myocarditis, 206 were deemed confirmed cases. The median age of people with confirmed myocarditis was 21 years (interquartile range [IQR], 16–32 years; range, 10–76 years); 129 were aged 24 years or younger (63%), 155 were male (75%). The median time from vaccination to symptom onset was two days (IQR, 1–4 days); 201 cases (98%) followed the administration of mRNA vaccines; five cases followed vaccination with AZD122. Forty‐six cases followed first vaccine doses (22%), 138 second doses (67%), and 22 cases third vaccine doses (11.0%). In 201 cases, people initially presented to emergency departments; 129 people were admitted to hospital (63%; median length of stay, two days; IQR, 1–3 days). Five people were admitted to intensive care. Echocardiographic abnormalities were identified in 26 of 200 patients (13%); electrocardiographic abnormalities were identified in 105 of 206 patients (51%; less frequently in female than male patients: adjusted odds ratio, 0.75; 95% confidence interval, 0.64–0.89). Troponin levels were elevated in 205 of 206 patients; the median increase was greater in male (95.3‐fold; IQR, 5.8–273‐fold) than female patients (9.9‐fold; IQR, 4.7–50‐fold). No cMRI abnormalities were found in patients for whom the troponin increase was threefold or less.
Conclusion
The clinical severity of COVID‐19 vaccine‐associated myocarditis in Victoria was generally mild. Markers of a more severe phenotype were more frequently recorded for male patients and people aged 24 years or younger. A threefold troponin increase could be used as a threshold for risk stratification of people with COVID‐19 vaccine‐associated myocarditis, especially in hospitals with limited access to cMRI facilities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Royal Children's Hospital Melbourne, Melbourne, VIC.
- Surveillance of Adverse Events Following Vaccination in the Community (SAEFVIC), Murdoch Children's Research Institute, Melbourne, VIC.
- Murdoch Children's Research Institute, Melbourne, VIC.
- Footscray Hospital, Melbourne, VIC.
- Melbourne Medical School, the University of Melbourne, Melbourne, VIC.
- Alfred Health, Melbourne, VIC.
ORCID-Profile: Hazel J Clothier, Daryl R Cheng
Zitieren
APA
Smith, J., Schrader, S., Morgan, H., Shenton, P., Alafaci, A., Cox, N., Taylor, A. J., Hare, J., Jones, B., Crawford, N. W., Buttery, J. P., Clothier, H. J., & Cheng, D. R. (2025). Clinical phenotype of COVID ‐19 vaccine‐associated myocarditis in Victoria, 2021–22: a cross‐sectional study. Medical Journal of Australia. https://doi.org/10.5694/mja2.52557
Vancouver
Smith J, Schrader S, Morgan H, Shenton P, Alafaci A, Cox N, et al. Clinical phenotype of COVID ‐19 vaccine‐associated myocarditis in Victoria, 2021–22: a cross‐sectional study. Medical Journal of Australia. 2025. doi:10.5694/mja2.52557
BibTeX
@article{Smith2025,
author = {Smith, Julia and Schrader, Silja and Morgan, Hannah and Shenton, Priya and Alafaci, Annette and Cox, Nicholas and Taylor, Andrew J and Hare, James and Jones, Bryn and Crawford, Nigel W and Buttery, Jim P and Clothier, Hazel J and Cheng, Daryl R},
title = {Clinical phenotype of COVID ‐19 vaccine‐associated myocarditis in Victoria, 2021–22: a cross‐sectional study},
journal = {Medical Journal of Australia},
year = {2025},
doi = {10.5694/mja2.52557}
}
EUVIMED